中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2012年
6期
309-313
,共5页
抗肿瘤治疗%药物性肝损伤
抗腫瘤治療%藥物性肝損傷
항종류치료%약물성간손상
Anti-tumor treatment%Drug induced liver injury
本文对抗肿瘤药物肝损伤的危险因素、诊断标准和临床分型、特异性易感基因检测的研究现状进行归纳,同时结合自身研究成果,总结抗肿瘤药肝损伤的防治措施,提出建设抗肿瘤药物肝损伤分子检测与临床评价技术平台,将对预测药物肝损伤的发生、指导临床化疗药物使用和新型药物开发具有重要的意义.
本文對抗腫瘤藥物肝損傷的危險因素、診斷標準和臨床分型、特異性易感基因檢測的研究現狀進行歸納,同時結閤自身研究成果,總結抗腫瘤藥肝損傷的防治措施,提齣建設抗腫瘤藥物肝損傷分子檢測與臨床評價技術平檯,將對預測藥物肝損傷的髮生、指導臨床化療藥物使用和新型藥物開髮具有重要的意義.
본문대항종류약물간손상적위험인소、진단표준화림상분형、특이성역감기인검측적연구현상진행귀납,동시결합자신연구성과,총결항종류약간손상적방치조시,제출건설항종류약물간손상분자검측여림상평개기술평태,장대예측약물간손상적발생、지도림상화료약물사용화신형약물개발구유중요적의의.
This review focused on the current understanding of anti-tumor drugs induced liver injury(DILI), and analyzed the risk factors of DILI, clinical diagnosis criterion, classification of DILI and the potential specific genes for DILI by review of the current literatures. Based on our own research results, the prevention and control measures for DILI in anti-tumor treatment were summarized. And building up the molecule test and clinical evaluation technical platform for antitumor drugs induced liver injury will be critical for predicting DILI, directing rational use of anti-tumor drugs and new drug development.
